This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Bristol-Myers Squibb Company

Drug Names(s): CXCL10, MDX-1100

Description: BMS-936557 (formerly MDX-1100) is a fully human antibody that is designed to target IP-10 (also known as CXCL10), a chemokine involved in the migration of activated T cells and monocytes into sites of inflammation and associated with multiple autoimmune disorders and inflammatory diseases such as rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Preclinical studies demonstrate that antibodies targeting IP-10 neutralize the effects of IP-10 and attenuate disease progression in animal models of ulcerative colitis and inflammatory bowel disease, as well as multiple sclerosis and rheumatoid arthritis.

Deal Structure: Medarex acquired full rights to MDX-1100 as part of its acquisition of Ability Biomedical in August 2004.

In July 2009, Bristol-Myers Squibb and Medarex announced that the companies signed a definitive merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb, for $16.00 per share in cash. The acquisition was closed in September 2009.

BMS-936557 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug